{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:35:43Z","timestamp":1789799743426,"version":"4.0.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This review explores the intricate landscape of neurodegenerative disease research, focusing on Amyotrophic Lateral Sclerosis (ALS) and the intersection of genetics and RNA biology to investigate the causative pathogenetic basis of this fatal disease. ALS is a severe neurodegenerative disease characterized by the progressive loss of motor neurons, leading to muscle weakness and paralysis. Despite significant research advances, the exact cause of ALS remains largely unknown. Thanks to the application of next-generation sequencing (NGS) approaches, it was possible to highlight the fundamental role of rare variants with large effect sizes and involvement of portions of non-coding RNA, providing valuable information on risk prediction, diagnosis, and treatment of age-related diseases, such as ALS. Genetic research has provided valuable insights into the pathophysiology of ALS, leading to the development of targeted therapies such as antisense oligonucleotides (ASOs). Regulatory agencies in several countries are evaluating the commercialization of Qalsody (Tofersen) for <jats:italic>SOD1<\/jats:italic>-associated ALS, highlighting the potential of gene-targeted therapies. Furthermore, the emerging significance of microRNAs (miRNAs) and long RNAs are of great interest. MiRNAs have emerged as promising biomarkers for diagnosing ALS and monitoring disease progression. Understanding the role of lncRNAs in the pathogenesis of ALS opens new avenues for therapeutic intervention. However, challenges remain in delivering RNA-based therapeutics to the central nervous system. Advances in genetic screening and personalized medicine hold promise for improving the management of ALS. Ongoing clinical trials use genomic approaches for patient stratification and drug targeting. Further research into the role of non-coding RNAs in the pathogenesis of ALS and their potential as therapeutic targets is crucial to the development of effective treatments for this devastating disease.<\/jats:p>","DOI":"10.1007\/s00415-025-12975-8","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:43:44Z","timestamp":1740545024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6246-5901","authenticated-orcid":false,"given":"Paola","family":"Ruffo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan J.","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Luisa","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"5","key":"12975_CR1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/ana.10369","volume":"52","author":"MD Alexander","year":"2002","unstructured":"Alexander MD, Traynor BJ, Miller N, Corr B, Frost E, McQuaid S, Brett FM, Green A, Hardiman O (2002) \u201cTrue\u201d sporadic ALS associated with a novel SOD-1 mutation. Ann Neurol 52(5):680\u2013683. https:\/\/doi.org\/10.1002\/ana.10369","journal-title":"Ann Neurol"},{"issue":"12","key":"12975_CR2","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","volume":"29","author":"DA Amado","year":"2021","unstructured":"Amado DA, Davidson BL (2021) Gene therapy for ALS: a review. Mol Ther 29(12):3345\u20133358. https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.008","journal-title":"Mol Ther"},{"issue":"11","key":"12975_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrneurol.2011.150","volume":"7","author":"PM Andersen","year":"2011","unstructured":"Andersen PM, Al-Chalabi A (2011) Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 7(11):603\u2013615. https:\/\/doi.org\/10.1038\/nrneurol.2011.150","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"12975_CR4","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1212\/WNL.0000000000004960","volume":"90","author":"M Benatar","year":"2018","unstructured":"Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, Schoenfeld D (2018) Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology 90(7):e565\u2013e574. https:\/\/doi.org\/10.1212\/WNL.0000000000004960","journal-title":"Neurology"},{"issue":"1","key":"12975_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.neuron.2015.06.012","volume":"87","author":"V Bernat","year":"2015","unstructured":"Bernat V, Disney MD (2015) RNA structures as mediators of neurological diseases and as drug targets. Neuron 87(1):28\u201346. https:\/\/doi.org\/10.1016\/j.neuron.2015.06.012","journal-title":"Neuron"},{"issue":"3","key":"12975_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working, G.","year":"2001","unstructured":"Biomarkers Definitions Working, G. (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89\u201395. https:\/\/doi.org\/10.1067\/mcp.2001.113989","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"12975_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023) Tofersen: first approval. Drugs 83(11):1039\u20131043. https:\/\/doi.org\/10.1007\/s40265-023-01904-6","journal-title":"Drugs"},{"issue":"1","key":"12975_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3233\/JAD-180482","volume":"67","author":"C Bonvicini","year":"2019","unstructured":"Bonvicini C, Scassellati C, Benussi L, Di Maria E, Maj C, Ciani M, Fostinelli S, Mega A, Bocchetta M, Lanzi G, Giacopuzzi E, Ferraboli S, Pievani M, Fedi V, Defanti CA, Giliani S, Frisoni GB, Ghidoni R, Gennarelli M, Alzheimer\u2019s Disease Neuroimaging, I. (2019) Next generation sequencing analysis in early onset dementia patients. J Alzheimers Dis 67(1):243\u2013256. https:\/\/doi.org\/10.3233\/JAD-180482","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"12975_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S1474-4422(12)70014-5","volume":"11","author":"S Byrne","year":"2012","unstructured":"Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C, McLaughlin RL, Iyer PM, O\u2019Brien C, Phukan J, Wynne B, Bokde AL, Bradley DG, Pender N, Al-Chalabi A, Hardiman O (2012) Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 11(3):232\u2013240. https:\/\/doi.org\/10.1016\/S1474-4422(12)70014-5","journal-title":"Lancet Neurol"},{"issue":"1","key":"12975_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(17)30401-5","volume":"17","author":"R Chia","year":"2018","unstructured":"Chia R, Chio A, Traynor BJ (2018) Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 17(1):94\u2013102. https:\/\/doi.org\/10.1016\/S1474-4422(17)30401-5","journal-title":"Lancet Neurol"},{"key":"12975_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2010.05.016","author":"A Chio","year":"2011","unstructured":"Chio A, Calvo A, Moglia C, Ossola I, Brunetti M, Sbaiz L, Lai SL, Abramzon Y, Traynor BJ, Restagno G (2011) A de novo missense mutation of the FUS gene in a \u201ctrue\u201d sporadic ALS case. Neurobiol Aging. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.05.016","journal-title":"Neurobiol Aging"},{"issue":"7","key":"12975_CR12","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.ymthe.2022.05.01","volume":"30","author":"BL Davidson","year":"2022","unstructured":"Davidson BL, Gao G, Berry-Kravis E, Bradbury AM, Bonnemann C, Buxbaum JD, Corcoran GR, Gray SJ, Gray-Edwards H, Kleiman RJ, Shaywitz AJ, Wang D, Zoghbi HY, Flotte TR, Tauscher-Wisniewski S, Tifft CJ, Sahin M, Gene Therapy Workshop, F. (2022) Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders. Mol Ther 30(7):2416\u20132428. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.01","journal-title":"Mol Ther"},{"issue":"4","key":"12975_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10048-014-0420-2","volume":"15","author":"B De Felice","year":"2014","unstructured":"De Felice B, Annunziata A, Fiorentino G, Borra M, Biffali E, Coppola C, Cotrufo R, Brettschneider J, Giordana ML, Dalmay T, Wheeler G, D\u2019Alessandro R (2014) miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics 15(4):243\u2013253. https:\/\/doi.org\/10.1007\/s10048-014-0420-2","journal-title":"Neurogenetics"},{"issue":"1","key":"12975_CR14","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1038\/s41598-020-61246-1","volume":"10","author":"N De Luna","year":"2020","unstructured":"De Luna N, Turon-Sans J, Cortes-Vicente E, Carrasco-Rozas A, Illan-Gala I, Dols-Icardo O, Clarimon J, Lleo A, Gallardo E, Illa I, Rojas-Garcia R (2020) Downregulation of miR-335-5P in amyotrophic lateral sclerosis can contribute to neuronal mitochondrial dysfunction and apoptosis. Sci Rep 10(1):4308. https:\/\/doi.org\/10.1038\/s41598-020-61246-1","journal-title":"Sci Rep"},{"issue":"1","key":"12975_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaneurol.2013.4544","volume":"71","author":"DC Dean 3rd","year":"2014","unstructured":"Dean DC 3rd, Jerskey BA, Chen K, Protas H, Thiyyagura P, Roontiva A, O\u2019Muircheartaigh J, Dirks H, Waskiewicz N, Lehman K, Siniard AL, Turk MN, Hua X, Madsen SK, Thompson PM, Fleisher AS, Huentelman MJ, Deoni SC, Reiman EM (2014) Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol 71(1):11\u201322. https:\/\/doi.org\/10.1001\/jamaneurol.2013.4544","journal-title":"JAMA Neurol"},{"issue":"7363","key":"12975_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nature10353","volume":"477","author":"HX Deng","year":"2011","unstructured":"Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, Jiang H, Hirano M, Rampersaud E, Jansen GH, Donkervoort S, Bigio EH, Brooks BR, Ajroud K, Sufit RL, Siddique T (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS\/dementia. Nature 477(7363):211\u2013215. https:\/\/doi.org\/10.1038\/nature10353","journal-title":"Nature"},{"issue":"4","key":"12975_CR17","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.apsb.2021.12.009","volume":"12","author":"Z Deng","year":"2022","unstructured":"Deng Z, Dong Y, Zhou X, Lu JH, Yue Z (2022) Pharmacological modulation of autophagy for Alzheimer\u2019s disease therapy: opportunities and obstacles. Acta Pharm Sin B 12(4):1688\u20131706. https:\/\/doi.org\/10.1016\/j.apsb.2021.12.009","journal-title":"Acta Pharm Sin B"},{"issue":"9","key":"12975_CR18","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1101\/gr.132159.111","volume":"22","author":"T Derrien","year":"2012","unstructured":"Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Guigo R (2012) The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22(9):1775\u20131789. https:\/\/doi.org\/10.1101\/gr.132159.111","journal-title":"Genome Res"},{"issue":"1","key":"12975_CR19","doi-asserted-by":"publisher","first-page":"CD006049","DOI":"10.1002\/14651858.CD006049.pub2","volume":"1","author":"A Diana","year":"2017","unstructured":"Diana A, Pillai R, Bongioanni P, O\u2019Keeffe AG, Miller RG, Moore DH (2017) Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis\/motor neuron disease. Cochrane Database Syst Rev 1(1):CD006049. https:\/\/doi.org\/10.1002\/14651858.CD006049.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"12975_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41420-020-00397-6","volume":"7","author":"G Dobrowolny","year":"2021","unstructured":"Dobrowolny G, Martone J, Lepore E, Casola I, Petrucci A, Inghilleri M, Morlando M, Colantoni A, Scicchitano BM, Calvo A, Bisogni G, Chio A, Sabatelli M, Bozzoni I, Musaro A (2021) A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients. Cell Death Discov 7(1):4. https:\/\/doi.org\/10.1038\/s41420-020-00397-6","journal-title":"Cell Death Discov"},{"key":"12975_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.598517","volume":"14","author":"J Dudman","year":"2020","unstructured":"Dudman J, Qi X (2020) Stress granule dysregulation in amyotrophic lateral sclerosis. Front Cell Neurosci 14:598517. https:\/\/doi.org\/10.3389\/fncel.2020.598517","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"12975_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnen\/nlw002","volume":"75","author":"A Elobeid","year":"2016","unstructured":"Elobeid A, Libard S, Leino M, Popova SN, Alafuzoff I (2016) Altered proteins in the aging brain. J Neuropathol Exp Neurol 75(4):316\u2013325. https:\/\/doi.org\/10.1093\/jnen\/nlw002","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"12975_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861\u2013874. https:\/\/doi.org\/10.1038\/nrg3074","journal-title":"Nat Rev Genet"},{"issue":"5","key":"12975_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","volume":"17","author":"T Fang","year":"2018","unstructured":"Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, Al-Chalabi A (2018) Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 17(5):416\u2013422. https:\/\/doi.org\/10.1016\/S1474-4422(18)30054-1","journal-title":"Lancet Neurol"},{"issue":"10360","key":"12975_CR25","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G (2022) Amyotrophic lateral sclerosis. Lancet 400(10360):1363\u20131380. https:\/\/doi.org\/10.1016\/S0140-6736(22)01272-7","journal-title":"Lancet"},{"key":"12975_CR26","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.2147\/IJN.S241055","volume":"15","author":"N Grafals-Ruiz","year":"2020","unstructured":"Grafals-Ruiz N, Rios-Vicil CI, Lozada-Delgado EL, Quinones-Diaz BI, Noriega-Rivera RA, Martinez-Zayas G, Santana-Rivera Y, Santiago-Sanchez GS, Valiyeva F, Vivas-Mejia PE (2020) Brain targeted gold liposomes improve RNAi delivery for glioblastoma. Int J Nanomedicine 15:2809\u20132828. https:\/\/doi.org\/10.2147\/IJN.S241055","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"12975_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF00313868","volume":"232","author":"SS Gubbay","year":"1985","unstructured":"Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y (1985) Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol 232(5):295\u2013300. https:\/\/doi.org\/10.1007\/BF00313868","journal-title":"J Neurol"},{"issue":"2","key":"12975_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1586\/ern.12.165","volume":"13","author":"AE Handel","year":"2013","unstructured":"Handel AE, Disanto G, Ramagopalan SV (2013) Next-generation sequencing in understanding complex neurological disease. Expert Rev Neurother 13(2):215\u2013227. https:\/\/doi.org\/10.1586\/ern.12.165","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"12975_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27(6):954\u2013963. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"issue":"Pt 3","key":"12975_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/brain\/118.3.707","volume":"118","author":"LJ Haverkamp","year":"1995","unstructured":"Haverkamp LJ, Appel V, Appel SH (1995) Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118(Pt 3):707\u2013719. https:\/\/doi.org\/10.1093\/brain\/118.3.707","journal-title":"Brain"},{"issue":"10","key":"12975_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA (2019) Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15(10):565\u2013581. https:\/\/doi.org\/10.1038\/s41582-019-0244-7","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"12975_CR32","doi-asserted-by":"publisher","first-page":"3117 e3111","DOI":"10.1016\/j.neurobiolaging.2015.08.005","volume":"36","author":"A Hubers","year":"2015","unstructured":"Hubers A, Just W, Rosenbohm A, Muller K, Marroquin N, Goebel I, Hogel J, Thiele H, Altmuller J, Nurnberg P, Weishaupt JH, Kubisch C, Ludolph AC, Volk AE (2015) De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients. Neurobiol Aging 36(11):3117 e3111-3117 e3116. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.08.005","journal-title":"Neurobiol Aging"},{"issue":"2","key":"12975_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrg2936","volume":"12","author":"E Huntzinger","year":"2011","unstructured":"Huntzinger E, Izaurralde E (2011) Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12(2):99\u2013110. https:\/\/doi.org\/10.1038\/nrg2936","journal-title":"Nat Rev Genet"},{"key":"12975_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-60761-938-3_4","volume":"686","author":"CE Johanson","year":"2011","unstructured":"Johanson CE, Stopa EG, McMillan PN (2011) The blood-cerebrospinal fluid barrier: structure and functional significance. Methods Mol Biol 686:101\u2013131. https:\/\/doi.org\/10.1007\/978-1-60761-938-3_4","journal-title":"Methods Mol Biol"},{"issue":"2","key":"12975_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pharmthera.2011.10.002","volume":"133","author":"E Junn","year":"2012","unstructured":"Junn E, Mouradian MM (2012) MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther 133(2):142\u2013150. https:\/\/doi.org\/10.1016\/j.pharmthera.2011.10.002","journal-title":"Pharmacol Ther"},{"issue":"1","key":"12975_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VA Korobeynikov","year":"2022","unstructured":"Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA (2022) Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med 28(1):104\u2013116. https:\/\/doi.org\/10.1038\/s41591-021-01615-z","journal-title":"Nat Med"},{"issue":"5918","key":"12975_CR37","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1126\/science.1166066","volume":"323","author":"TJ Kwiatkowski Jr","year":"2009","unstructured":"Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Brown RH Jr (2009) Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323(5918):1205\u20131208. https:\/\/doi.org\/10.1126\/science.1166066","journal-title":"Science"},{"issue":"6","key":"12975_CR38","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ana.24950","volume":"81","author":"DJ Lange","year":"2017","unstructured":"Lange DJ, Shahbazi M, Silani V, Ludolph AC, Weishaupt JH, Ajroud-Driss S, Fields KG, Remanan R, Appel SH, Morelli C, Doretti A, Maderna L, Messina S, Weiland U, Marklund SL, Andersen PM (2017) Pyrimethamine significantly lowers cerebrospinal fluid Cu\/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann Neurol 81(6):837\u2013848. https:\/\/doi.org\/10.1002\/ana.24950","journal-title":"Ann Neurol"},{"key":"12975_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/978-1-0716-3163-8_24","volume":"2660","author":"MM Li","year":"2023","unstructured":"Li MM, Awasthi S, Ghosh S, Bisht D, Coban Akdemir ZH, Sheynkman GM, Sahni N, Yi SS (2023) Gain-of-function variomics and multi-omics network biology for precision medicine. Methods Mol Biol 2660:357\u2013372. https:\/\/doi.org\/10.1007\/978-1-0716-3163-8_24","journal-title":"Methods Mol Biol"},{"issue":"6","key":"12975_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrc3932","volume":"15","author":"S Lin","year":"2015","unstructured":"Lin S, Gregory RI (2015) MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 15(6):321\u2013333. https:\/\/doi.org\/10.1038\/nrc3932","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"12975_CR41","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.devcel.2010.03.010","volume":"18","author":"N Liu","year":"2010","unstructured":"Liu N, Olson EN (2010) MicroRNA regulatory networks in cardiovascular development. Dev Cell 18(4):510\u2013525. https:\/\/doi.org\/10.1016\/j.devcel.2010.03.010","journal-title":"Dev Cell"},{"issue":"4","key":"12975_CR42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/jnnp.2009.183525","volume":"81","author":"G Logroscino","year":"2010","unstructured":"Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, Millul A, Benn E, Beghi E (2010) Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 81(4):385\u2013390. https:\/\/doi.org\/10.1136\/jnnp.2009.183525","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"12975_CR43","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C Lopez-Otin","year":"2013","unstructured":"Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153(6):1194\u20131217. https:\/\/doi.org\/10.1016\/j.cell.2013.05.039","journal-title":"Cell"},{"key":"12975_CR44","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.18.604174","author":"G Lv","year":"2024","unstructured":"Lv G, Sayles NM, Huang Y, Mancinelli CD, McAvoy K, Shneider NA, Manfredi G, Kawamata H, Eliezer D (2024) Amyloid fibril structures link CHCHD10 and CHCHD2 to neurodegeneration. bioRxiv. https:\/\/doi.org\/10.1101\/2024.07.18.604174","journal-title":"bioRxiv"},{"issue":"R2","key":"12975_CR45","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1093\/hmg\/ddq365","volume":"19","author":"DG MacArthur","year":"2010","unstructured":"MacArthur DG, Tyler-Smith C (2010) Loss-of-function variants in the genomes of healthy humans. Hum Mol Genet 19(R2):R125-130. https:\/\/doi.org\/10.1093\/hmg\/ddq365","journal-title":"Hum Mol Genet"},{"issue":"4","key":"12975_CR46","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1042\/BST20170501","volume":"46","author":"R Macdonald","year":"2018","unstructured":"Macdonald R, Barnes K, Hastings C, Mortiboys H (2018) Mitochondrial abnormalities in Parkinson\u2019s disease and Alzheimer\u2019s disease: can mitochondria be targeted therapeutically? Biochem Soc Trans 46(4):891\u2013909. https:\/\/doi.org\/10.1042\/BST20170501","journal-title":"Biochem Soc Trans"},{"key":"12975_CR47","doi-asserted-by":"publisher","first-page":"34802","DOI":"10.1038\/srep34802","volume":"6","author":"A Magri","year":"2016","unstructured":"Magri A, Belfiore R, Reina S, Tomasello MF, Di Rosa MC, Guarino F, Leggio L, De Pinto V, Messina A (2016) Hexokinase I N-terminal based peptide prevents the VDAC1-SOD1 G93A interaction and re-establishes ALS cell viability. Sci Rep 6:34802. https:\/\/doi.org\/10.1038\/srep34802","journal-title":"Sci Rep"},{"key":"12975_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah3924","author":"M Maier","year":"2018","unstructured":"Maier M, Welt T, Wirth F, Montrasio F, Preisig D, McAfoose J, Vieira FG, Kulic L, Spani C, Stehle T, Perrin S, Weber M, Hock C, Nitsch RM, Grimm J (2018) A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aah3924","journal-title":"Sci Transl Med"},{"issue":"6435","key":"12975_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.aav9776","volume":"364","author":"S Maniatis","year":"2019","unstructured":"Maniatis S, Aijo T, Vickovic S, Braine C, Kang K, Mollbrink A, Fagegaltier D, Andrusivova Z, Saarenpaa S, Saiz-Castro G, Cuevas M, Watters A, Lundeberg J, Bonneau R, Phatnani H (2019) Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science 364(6435):89\u201393. https:\/\/doi.org\/10.1126\/science.aav9776","journal-title":"Science"},{"issue":"7265","key":"12975_CR50","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nature08494","volume":"461","author":"TA Manolio","year":"2009","unstructured":"Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Visscher PM (2009) Finding the missing heritability of complex diseases. Nature 461(7265):747\u2013753. https:\/\/doi.org\/10.1038\/nature08494","journal-title":"Nature"},{"issue":"3","key":"12975_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2016.117","volume":"16","author":"M Matsui","year":"2017","unstructured":"Matsui M, Corey DR (2017) Non-coding RNAs as drug targets. Nat Rev Drug Discov 16(3):167\u2013179. https:\/\/doi.org\/10.1038\/nrd.2016.117","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"12975_CR52","doi-asserted-by":"publisher","first-page":"232","DOI":"10.31662\/jmaj.2021-0019","volume":"4","author":"M Matsuo","year":"2021","unstructured":"Matsuo M (2021) Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from duchenne muscular dystrophy. JMA J 4(3):232\u2013240. https:\/\/doi.org\/10.31662\/jmaj.2021-0019","journal-title":"JMA J"},{"issue":"15","key":"12975_CR53","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1212\/WNL.0b013e3181bc01a4","volume":"73","author":"RG Miller","year":"2009","unstructured":"Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC, Quality Standards Subcommittee of the American Academy of, N. (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive\/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73(15):1227\u20131233. https:\/\/doi.org\/10.1212\/WNL.0b013e3181bc01a4","journal-title":"Neurology"},{"issue":"12","key":"12975_CR54","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chio A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Group, O. L. E. W. (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387(12):1099\u20131110. https:\/\/doi.org\/10.1056\/NEJMoa2204705","journal-title":"N Engl J Med"},{"issue":"5","key":"12975_CR55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12(5):435\u2013442. https:\/\/doi.org\/10.1016\/S1474-4422(13)70061-9","journal-title":"Lancet Neurol"},{"issue":"2","key":"12975_CR56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMoa2005056","volume":"383","author":"C Mueller","year":"2020","unstructured":"Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM, Douthwright CL, Gelevski D, Luppino SD, Blackwood M, Wightman NS, Oakley DH, Frosch MP, Flotte TR, Cudkowicz ME, Brown RH Jr (2020) SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N Engl J Med 383(2):151\u2013158. https:\/\/doi.org\/10.1056\/NEJMoa2005056","journal-title":"N Engl J Med"},{"issue":"2","key":"12975_CR57","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/jnnp-2021-327520","volume":"93","author":"K Muller","year":"2022","unstructured":"Muller K, Oh KW, Nordin A, Panthi S, Kim SH, Nordin F, Freischmidt A, Ludolph AC, Ki CS, Forsberg K, Weishaupt J, Kim YE, Andersen PM (2022) De novo mutations in SOD1 are a cause of ALS. J Neurol Neurosurg Psychiatry 93(2):201\u2013206. https:\/\/doi.org\/10.1136\/jnnp-2021-327520","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"12975_CR58","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.3390\/molecules20057775","volume":"20","author":"N Nagoshi","year":"2015","unstructured":"Nagoshi N, Nakashima H, Fehlings MG (2015) Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside. Molecules 20(5):7775\u20137789. https:\/\/doi.org\/10.3390\/molecules20057775","journal-title":"Molecules"},{"issue":"5796","key":"12975_CR59","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130\u2013133. https:\/\/doi.org\/10.1126\/science.1134108","journal-title":"Science"},{"issue":"8","key":"12975_CR60","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nm.3232","volume":"19","author":"RA Nixon","year":"2013","unstructured":"Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med 19(8):983\u2013997. https:\/\/doi.org\/10.1038\/nm.3232","journal-title":"Nat Med"},{"key":"12975_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103464","author":"J Pham","year":"2020","unstructured":"Pham J, Keon M, Brennan S, Saksena N (2020) Connecting RNA-modifying similarities of TDP-43, FUS, and SOD1 with microRNA dysregulation amidst a renewed network perspective of amyotrophic lateral sclerosis proteinopathy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21103464","journal-title":"Int J Mol Sci"},{"key":"12975_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.714768","volume":"14","author":"R Policarpo","year":"2021","unstructured":"Policarpo R, Sierksma A, De Strooper B, d\u2019Ydewalle C (2021) From junk to function: LncRNAs in CNS health and disease. Front Mol Neurosci 14:714768. https:\/\/doi.org\/10.3389\/fnmol.2021.714768","journal-title":"Front Mol Neurosci"},{"issue":"8","key":"12975_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000617","volume":"5","author":"J Ponjavic","year":"2009","unstructured":"Ponjavic J, Oliver PL, Lunter G, Ponting CP (2009) Genomic and transcriptional co-localization of protein-coding and long non-coding RNA pairs in the developing brain. PLoS Genet 5(8):e1000617. https:\/\/doi.org\/10.1371\/journal.pgen.1000617","journal-title":"PLoS Genet"},{"issue":"1","key":"12975_CR64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00401-015-1436-x","volume":"130","author":"C Pottier","year":"2015","unstructured":"Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R, Brown P, Ravenscroft T, van Blitterswijk M, Nicholson AM, DeTure M, Knopman DS, Josephs KA, Parisi JE, Petersen RC, Boylan KB, Boeve BF, Graff-Radford NR, Veltman JA, Rademakers R (2015) Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol 130(1):77\u201392. https:\/\/doi.org\/10.1007\/s00401-015-1436-x","journal-title":"Acta Neuropathol"},{"issue":"5","key":"12975_CR65","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10620-017-4506-1","volume":"62","author":"C Richard Boland","year":"2017","unstructured":"Richard Boland C (2017) Non-coding RNA: it\u2019s not junk. Dig Dis Sci 62(5):1107\u20131109. https:\/\/doi.org\/10.1007\/s10620-017-4506-1","journal-title":"Dig Dis Sci"},{"issue":"10","key":"12975_CR66","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 19(10):673\u2013694. https:\/\/doi.org\/10.1038\/s41573-020-0075-7","journal-title":"Nat Rev Drug Discov"},{"issue":"6415","key":"12975_CR67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O\u2019Regan JP, Deng HX et al (1993) Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362(6415):59\u201362. https:\/\/doi.org\/10.1038\/362059a0","journal-title":"Nature"},{"key":"12975_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12050758","author":"P Ruffo","year":"2022","unstructured":"Ruffo P, Cavallaro S, Conforti FL (2022) The advent of omics sciences in clinical trials of motor neuron diseases. J Pers Med. https:\/\/doi.org\/10.3390\/jpm12050758","journal-title":"J Pers Med"},{"key":"12975_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.784996","volume":"12","author":"P Ruffo","year":"2021","unstructured":"Ruffo P, Strafella C, Cascella R, Caputo V, Conforti FL, Ando S, Giardina E (2021) Deregulation of ncRNA in neurodegenerative disease: focus on circRNA, lncRNA and miRNA in amyotrophic lateral sclerosis. Front Genet 12:784996. https:\/\/doi.org\/10.3389\/fgene.2021.784996","journal-title":"Front Genet"},{"issue":"3","key":"12975_CR70","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1152\/physrev.00006.2010","volume":"91","author":"D Sayed","year":"2011","unstructured":"Sayed D, Abdellatif M (2011) MicroRNAs in development and disease. Physiol Rev 91(3):827\u2013887. https:\/\/doi.org\/10.1152\/physrev.00006.2010","journal-title":"Physiol Rev"},{"key":"12975_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52264","author":"SE Smith","year":"2025","unstructured":"Smith SE, McCoy-Gross K, Malcolm A, Oranski J, Markway JW, Miller TM, Bucelli RC (2025) Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a \u201creal-world\u201d setting. Ann Clin Transl Neurol. https:\/\/doi.org\/10.1002\/acn3.52264","journal-title":"Ann Clin Transl Neurol"},{"key":"12975_CR72","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.expneurol.2015.07.027","volume":"273","author":"R Spector","year":"2015","unstructured":"Spector R, Robert Snodgrass S, Johanson CE (2015) A balanced view of the cerebrospinal fluid composition and functions: focus on adult humans. Exp Neurol 273:57\u201368. https:\/\/doi.org\/10.1016\/j.expneurol.2015.07.027","journal-title":"Exp Neurol"},{"issue":"5870","key":"12975_CR73","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1126\/science.1154584","volume":"319","author":"J Sreedharan","year":"2008","unstructured":"Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319(5870):1668\u20131672. https:\/\/doi.org\/10.1126\/science.1154584","journal-title":"Science"},{"key":"12975_CR74","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","volume":"138","author":"EO Talbott","year":"2016","unstructured":"Talbott EO, Malek AM, Lacomis D (2016) The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol 138:225\u2013238. https:\/\/doi.org\/10.1016\/B978-0-12-802973-2.00013-6","journal-title":"Handb Clin Neurol"},{"issue":"19","key":"12975_CR75","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.4103\/0366-6999.215323","volume":"130","author":"QQ Tao","year":"2017","unstructured":"Tao QQ, Wu ZY (2017) Amyotrophic lateral sclerosis: precise diagnosis and individualized treatment. Chin Med J (Engl) 130(19):2269\u20132272. https:\/\/doi.org\/10.4103\/0366-6999.215323","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"12975_CR76","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1158\/1055-9965.EPI-06-0146","volume":"15","author":"DC Thomas","year":"2006","unstructured":"Thomas DC (2006) Are we ready for genome-wide association studies? Cancer Epidemiol Biomarkers Prev 15(4):595\u2013598. https:\/\/doi.org\/10.1158\/1055-9965.EPI-06-0146","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"12975_CR77","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-394287-6.00002-1","volume":"89","author":"R Thompson","year":"2012","unstructured":"Thompson R, Drew CJ, Thomas RH (2012) Next generation sequencing in the clinical domain: clinical advantages, practical, and ethical challenges. Adv Protein Chem Struct Biol 89:27\u201363. https:\/\/doi.org\/10.1016\/B978-0-12-394287-6.00002-1","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"4","key":"12975_CR78","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00415-003-1026-z","volume":"250","author":"BJ Traynor","year":"2003","unstructured":"Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O (2003) An outcome study of riluzole in amyotrophic lateral sclerosis\u2013a population-based study in Ireland, 1996\u20132000. J Neurol 250(4):473\u2013479. https:\/\/doi.org\/10.1007\/s00415-003-1026-z","journal-title":"J Neurol"},{"issue":"9","key":"12975_CR79","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1093\/brain\/awz217","volume":"142","author":"GE Tyzack","year":"2019","unstructured":"Tyzack GE, Luisier R, Taha DM, Neeves J, Modic M, Mitchell JS, Meyer I, Greensmith L, Newcombe J, Ule J, Luscombe NM, Patani R (2019) Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain 142(9):2572\u20132580. https:\/\/doi.org\/10.1093\/brain\/awz217","journal-title":"Brain"},{"key":"12975_CR80","unstructured":"uniQure (2024) uniQure Announces Dosing of First Patient in Phase I\/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS. https:\/\/uniqure.gcs-web.com\/news-releases\/news-release-details\/uniqure-announces-dosing-first-patient-phase-iii-clinical-trial"},{"issue":"6","key":"12975_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16264","volume":"31","author":"P Van Damme","year":"2024","unstructured":"Van Damme P, Al-Chalabi A, Andersen PM, Chio A, Couratier P, De Carvalho M, Hardiman O, Kuzma-Kozakiewicz M, Ludolph A, McDermott CJ, Mora JS, Petri S, Probyn K, Reviers E, Salachas F, Silani V, Tysnes OB, van den Berg LH, Villanueva G, Weber M (2024) European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). Eur J Neurol 31(6):e16264. https:\/\/doi.org\/10.1111\/ene.16264","journal-title":"Eur J Neurol"},{"key":"12975_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.679199","volume":"15","author":"F Verde","year":"2021","unstructured":"Verde F, Otto M, Silani V (2021) Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci 15:679199. https:\/\/doi.org\/10.3389\/fnins.2021.679199","journal-title":"Front Neurosci"},{"issue":"1","key":"12975_CR83","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s13311-016-0503-x","volume":"14","author":"LT Vu","year":"2017","unstructured":"Vu LT, Bowser R (2017) Fluid-based biomarkers for amyotrophic lateral sclerosis. Neurotherapeutics 14(1):119\u2013134. https:\/\/doi.org\/10.1007\/s13311-016-0503-x","journal-title":"Neurotherapeutics"},{"key":"12975_CR84","doi-asserted-by":"publisher","first-page":"11253","DOI":"10.1038\/ncomms11253","volume":"7","author":"KL Williams","year":"2016","unstructured":"Williams KL, Topp S, Yang S, Smith B, Fifita JA, Warraich ST, Zhang KY, Farrawell N, Vance C, Hu X, Chesi A, Leblond CS, Lee A, Rayner SL, Sundaramoorthy V, Dobson-Stone C, Molloy MP, van Blitterswijk M, Dickson DW, Blair IP (2016) CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Commun 7:11253. https:\/\/doi.org\/10.1038\/ncomms11253","journal-title":"Nat Commun"},{"issue":"8","key":"12975_CR85","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA (2021) Noncoding RNA therapeutics\u2014challenges and potential solutions. Nat Rev Drug Discov 20(8):629\u2013651. https:\/\/doi.org\/10.1038\/s41573-021-00219-z","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"12975_CR86","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"G Writing","year":"2017","unstructured":"Writing G, Edaravone ALSSG (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505\u2013512. https:\/\/doi.org\/10.1016\/S1474-4422(17)30115-1","journal-title":"Lancet Neurol"},{"issue":"1","key":"12975_CR87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12929-020-00636-z","volume":"27","author":"YY Wu","year":"2020","unstructured":"Wu YY, Kuo HC (2020) Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases. J Biomed Sci 27(1):49. https:\/\/doi.org\/10.1186\/s12929-020-00636-z","journal-title":"J Biomed Sci"},{"issue":"7628","key":"12975_CR88","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nature20411","volume":"539","author":"T Wyss-Coray","year":"2016","unstructured":"Wyss-Coray T (2016) Ageing, neurodegeneration and brain rejuvenation. Nature 539(7628):180\u2013186. https:\/\/doi.org\/10.1038\/nature20411","journal-title":"Nature"},{"issue":"1","key":"12975_CR89","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12859-020-3496-8","volume":"21","author":"Q Yuan","year":"2020","unstructured":"Yuan Q, Guo X, Ren Y, Wen X, Gao L (2020) Cluster correlation based method for lncRNA-disease association prediction. BMC Bioinform 21(1):180. https:\/\/doi.org\/10.1186\/s12859-020-3496-8","journal-title":"BMC Bioinform"},{"key":"12975_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2019.6","volume":"6","author":"S Zucca","year":"2019","unstructured":"Zucca S, Gagliardi S, Pandini C, Diamanti L, Bordoni M, Sproviero D, Arigoni M, Olivero M, Pansarasa O, Ceroni M, Calogero R, Cereda C (2019) RNA-Seq profiling in peripheral blood mononuclear cells of amyotrophic lateral sclerosis patients and controls. Sci Data 6:190006. https:\/\/doi.org\/10.1038\/sdata.2019.6","journal-title":"Sci Data"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12975-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:40:49Z","timestamp":1742233249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12975-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12975"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12975-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BJT holds patents on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion of C9orf72, and has a patent pending (U.S. Patent Application No. 63\/717,807) on the diagnostic testing for ALS based on the proteomic panel. The authors declare no other competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"233"}}